Osaka, Japan-based Takeda Pharmaceutical (TYO: 4502) has released interim data from a Phase II trial into its dengue vaccine candidate TAK-003. The full analysis has been published in The Lancet.
The data showed two doses of the vaccine candidate induced antibody responses against all four types of dengue virus in a large population aged 2-17. The company said that no safety concerns were observed.
“The levels of immunogenicity induced by TAK-003 against all four dengue serotypes, even in seronegative participants, are encouraging because seropositivity after vaccination may be an important measure of vaccine performance,” said Xavier Sáez-Llorens, director of clinical research at the Panama Children’s Hospital.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze